Sign In
Buy ARDX
$6.18
-0.190 (-2.98%)
At Close: Jun 23, 2026
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 19'th Feb 2026
IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs fo
Insights Into Ardelyx (ARDX) Q4: Wall Street Projections for Key Metrics
10:16am, Tuesday, 17'th Feb 2026
Besides Wall Street's top-and-bottom-line estimates for Ardelyx (ARDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qua
Short Interest in Ardelyx, Inc. (NASDAQ:ARDX) Declines By 15.0%
02:14am, Monday, 16'th Feb 2026
Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 18,557,299 sha
Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:05am, Thursday, 12'th Feb 2026
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Projected to Post Quarterly Earnings on Thursday
04:06am, Thursday, 12'th Feb 2026
Ardelyx (NASDAQ: ARDX - Get Free Report) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect Ardelyx to post earnings of $0.02 per share a
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
08:00am, Thursday, 05'th Feb 2026
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Ardelyx Receives New Patent for Tenapanor
08:29am, Tuesday, 03'rd Feb 2026
WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
08:29am, Wednesday, 28'th Jan 2026
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
All You Need to Know About Ardelyx (ARDX) Rating Upgrade to Buy
01:00pm, Monday, 26'th Jan 2026
Ardelyx (ARDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ardelyx (NASDAQ:ARDX) Sets New 1-Year High After Analyst Upgrade
01:21am, Thursday, 22'nd Jan 2026
Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report)'s share price reached a new 52-week high on Wednesday after Wedbush raised their price target on the stock from $16.00 to $19.00. Wedbush currently has a
Ardelyx: Assessment Of Acquisition Rumors
01:04pm, Wednesday, 21'st Jan 2026
Ardelyx: Assessment Of Acquisition Rumors
Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength?
08:22am, Wednesday, 21'st Jan 2026
Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th
Ardelyx: IBSRELA Momentum Drives Opportunity
06:14am, Tuesday, 20'th Jan 2026
Ardelyx has transformed into a commercial powerhouse with two FDA-approved, first-in-class drugs, IBSRELA and XPHOZAH, driving robust revenue growth. IBSRELA's rapid uptake and projected $410–$430 m
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?
10:40am, Monday, 12'th Jan 2026
Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Laura Williams Sells 50,000 Shares of Ardelyx (NASDAQ:ARDX) Stock
04:56am, Sunday, 11'th Jan 2026
Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) insider Laura Williams sold 50,000 shares of the business's stock in a transaction on Thursday, January 8th. The shares were sold at an average price of
